Which has higher valuation and earnings, SISI or TRVN?

Shineco has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shineco $9.60M 0.00 -$22.45M -$204.00 N/A Trevena $443K 0.14 -$40.29M -$47.04 N/A

Is SISI or TRVN more profitable?

Trevena has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Trevena's return on equity of 0.00% beat Shineco's return on equity. Company Net Margins Return on Equity Return on Assets Shineco -380.55% -79.89% -33.01% Trevena N/A N/A -119.55%

Do analysts prefer CDT or TRVN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trevena 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, CDT or TRVN?

CDT Equity has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$83.86 thousand N/A Trevena $443K 0.14 -$40.29M -$47.04 N/A

Is CDT or TRVN more profitable?

Trevena's return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -72.25% -55.44% Trevena N/A N/A -119.55%

Is TRVN or BPTH more profitable?

Trevena's return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Bio-Path N/A -2,842.40% -337.48%

Is CARM or TRVN more profitable?

Trevena has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% Trevena N/A N/A -119.55%

Which has stronger valuation & earnings, SCPS or TRVN?

Scopus BioPharma has higher earnings, but lower revenue than Trevena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Trevena $443K 0.14 -$40.29M -$47.04 N/A

Is SCPS or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Trevena N/A N/A -119.55%

Trevena (TRVN) Competitors

$0.07 0.00 (0.00%)

As of 10/12/2026 02:57 PM Eastern

Compare

TRVN vs. SISI, CDT, BPTH, CARM, and SCPS

Should you buy Trevena stock or one of its competitors? Trevena's main competitors and comparable companies include Shineco (SISI), CDT Equity (CDT), Bio-Path (BPTH), Carisma Therapeutics (CARM), and Scopus BioPharma (SCPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trevena compare to Shineco?

Shineco (NASDAQ:SISI) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Shineco has a beta of -1.76, suggesting that its share price is 276% less volatile than the broader market. Comparatively, Trevena has a beta of -1.99, suggesting that its share price is 299% less volatile than the broader market.

Trevena has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Trevena's return on equity of 0.00% beat Shineco's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shineco	-380.55%	-79.89%	-33.01%
Trevena	N/A	N/A	-119.55%

4.1% of Shineco shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 0.0% of Shineco shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Trevena's average media sentiment score of 0.48 beat Shineco's score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company	Overall Sentiment
Shineco	Neutral
Trevena	Neutral

Shineco has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shineco	$9.60M	0.00	-$22.45M	-$204.00	N/A
Trevena	$443K	0.14	-$40.29M	-$47.04	N/A

Summary

Trevena beats Shineco on 7 of the 12 factors compared between the two stocks.

How does Trevena compare to CDT Equity?

CDT Equity (NASDAQ:CDT) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

CDT Equity has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Trevena has a beta of -1.99, suggesting that its share price is 299% less volatile than the broader market.

Trevena's return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-72.25%	-55.44%
Trevena	N/A	N/A	-119.55%

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 7.3% of CDT Equity shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, CDT Equity had 3 more articles in the media than Trevena. MarketBeat recorded 3 mentions for CDT Equity and 0 mentions for Trevena. CDT Equity's average media sentiment score of 1.32 beat Trevena's score of 0.48 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Positive
Trevena	Neutral

CDT Equity has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$83.86 thousand	N/A
Trevena	$443K	0.14	-$40.29M	-$47.04	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trevena	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CDT Equity beats Trevena on 7 of the 11 factors compared between the two stocks.

How does Trevena compare to Bio-Path?

Trevena (NASDAQ:TRVN) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Trevena has a beta of -1.99, suggesting that its stock price is 299% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.44, suggesting that its stock price is 144% less volatile than the broader market.

13.6% of Trevena shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bio-Path has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	0.14	-$40.29M	-$47.04	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Trevena's return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Bio-Path	N/A	-2,842.40%	-337.48%

In the previous week, Trevena's average media sentiment score of 0.48 beat Bio-Path's score of 0.00 indicating that Trevena is being referred to more favorably in the media.

Company	Overall Sentiment
Trevena	Neutral
Bio-Path	Neutral

Summary

Trevena beats Bio-Path on 6 of the 10 factors compared between the two stocks.

How does Trevena compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Carisma Therapeutics has a beta of -9.6, suggesting that its stock price is 1,060% less volatile than the broader market. Comparatively, Trevena has a beta of -1.99, suggesting that its stock price is 299% less volatile than the broader market.

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Trevena has lower revenue, but higher earnings than Carisma Therapeutics. Trevena is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Trevena	$443K	0.14	-$40.29M	-$47.04	N/A

Trevena has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Trevena	N/A	N/A	-119.55%

In the previous week, Trevena's average media sentiment score of 0.48 beat Carisma Therapeutics' score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Trevena	Neutral

Summary

Trevena beats Carisma Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Trevena compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Scopus BioPharma has higher earnings, but lower revenue than Trevena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Trevena	$443K	0.14	-$40.29M	-$47.04	N/A

In the previous week, Trevena's average media sentiment score of 0.48 beat Scopus BioPharma's score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Trevena	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

13.6% of Trevena shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Scopus BioPharma has a beta of -0.32, indicating that its stock price is 132% less volatile than the broader market. Comparatively, Trevena has a beta of -1.99, indicating that its stock price is 299% less volatile than the broader market.

Summary

Scopus BioPharma beats Trevena on 4 of the 7 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVN vs. The Competition

Export

Metric	Trevena	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$63K	$12.38B	$7.27B	$13.21B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	0.00	628.06	195.99	19.34
Price / Sales	0.14	747.12	562.25	81.55
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	-0.01	9.20	10.71	6.03
Net Income	-$40.29M	$2.83B	$3.50B	$380.34M
7 Day Performance	N/A	-3.42%	-2.90%	-2.32%
1 Month Performance	N/A	-7.48%	-7.37%	-5.29%
1 Year Performance	N/A	-5.59%	3.05%	-2.94%

Trevena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVN Trevena	N/A	$0.07 flat	N/A	+450.0%	$63K	$443K	N/A	23
SISI Shineco	N/A	$0.11 flat	N/A	-88.3%	$44K	$9.60M	N/A	119
CDT CDT Equity	0.9279 of 5 stars	$0.84 -10.1%	N/A	-100.0%	$30K	N/A	N/A	4	Short Interest Decrease
BPTH Bio-Path	N/A	$0.00 flat	N/A	-99.6%	$27K	N/A	N/A	10	Gap Up
CARM Carisma Therapeutics	N/A	$0.00 flat	N/A	-98.9%	$21K	$10.77M	0.00	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVN) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevena (TRVN) Competitors